Ascendia is a specialty CDMO company dedicated to developing enhanced formulations of existing drug products, and enabling formulations for preclinical and clinical stage drug candidates. Ascendia provides state-of-the-art formulation development services for poorly water soluble molecules, and cGMP manufacture of clinical trial materials. Applying its nano-particle technologies and expertise, Ascendia can rapidly assess the feasibility of a broad array of formulation options in order to improve a drug’s bioavailability and/or stability. Our technologies include nano-emulsions, amorphous solid dispersions, oral controlled release, self-emulsifying drug delivery systems (SEDDs) and production of nanoparticles (including LNPs). Ascendia provides development and testing services – from pre-formulation through to manufacture of pilot clinical supplies.

We execute rapid, comprehensive, and cost-effective programs for our clients. We partner with emerging, discovery-stage pharmaceutical companies to provide early-stage formulations; with pharma and biotech companies for formulation development, optimization and clinical trial manufacturing; with generic companies that seek enabling technology for complex product development projects; and with specialty pharmaceutical companies that need development of new 505(b)(2) products for clinical testing.